The IPO of Sai Life Sciences, a pharma company offering its services globally, has opened for bidding and has received a mixed set of reviews from investors. While SBI Securities recommends subscribing for long-term investment, Swastika Investmart has a cautious rating due to the high valuation and limited direct benefits to the company. Nirmal Bang Securities also recommends subscribing for long-term, citing the company's strong financial performance and potential for improvement in operating margins.